| Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma MV Mateos, MT Hernández, P Giraldo, J De la Rubia, F De Arriba, ... New England Journal of Medicine 369 (5), 438-447, 2013 | 649 | 2013 |
| Treatment of Fabry’s disease with the pharmacologic chaperone migalastat DP Germain, DA Hughes, K Nicholls, DG Bichet, R Giugliani, WR Wilcox, ... New england journal of medicine 375 (6), 545-555, 2016 | 642 | 2016 |
| Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib C Gambacorti-Passerini, L Antolini, FX Mahon, F Guilhot, M Deininger, ... Journal of the National Cancer Institute 103 (7), 553-561, 2011 | 540 | 2011 |
| High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a … J Bladé, L Rosiñol, A Sureda, JM Ribera, J Díaz-Mediavilla, ... Blood 106 (12), 3755-3759, 2005 | 414 | 2005 |
| MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia C Jiménez, E Sebastián, MC Chillón, P Giraldo, J Mariano Hernández, ... Leukemia 27 (8), 1722-1728, 2013 | 311 | 2013 |
| Resumen: Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID-19 en establecimientos de atención de la salud CHS Trujillo Infectio, 2020 | 266 | 2020 |
| Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease A Zimran, E Brill-Almon, R Chertkoff, M Petakov, F Blanco-Favela, ... Blood, The Journal of the American Society of Hematology 118 (22), 5767-5773, 2011 | 253 | 2011 |
| Age and d PCR can predict relapse in CML patients who discontinued imatinib: The ISAV study S Mori, E Vagge, P Le Coutre, E Abruzzese, B Martino, E Pungolino, ... American journal of hematology 90 (10), 910-914, 2015 | 240 | 2015 |
| Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 … MV Mateos, MT Hernández, P Giraldo, J de la Rubia, F de Arriba, ... The lancet oncology 17 (8), 1127-1136, 2016 | 198 | 2016 |
| Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients NJ Weinreb, MC Aggio, HC Andersson, G Andria, J Charrow, JTR Clarke, ... Seminars in hematology 41, 15-22, 2004 | 188 | 2004 |
| Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the … HK Al-Ali, M Griesshammer, P le Coutre, CF Waller, AM Liberati, ... haematologica 101 (9), 1065, 2016 | 184 | 2016 |
| A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma MT Petrucci, P Giraldo, P Corradini, A Teixeira, MA Dimopoulos, IW Blau, ... British journal of haematology 160 (5), 649-659, 2013 | 176 | 2013 |
| Miglustat (NB-DNJ) works as a chaperone for mutated acid β-glucosidase in cells transfected with several Gaucher disease mutations P Alfonso, S Pampín, J Estrada, JC Rodríguez-Rey, P Giraldo, J Sancho, ... Blood Cells, Molecules, and Diseases 35 (2), 268-276, 2005 | 163 | 2005 |
| Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1‐year phase 1 … R Schiffmann, O Goker‐Alpan, M Holida, P Giraldo, L Barisoni, RB Colvin, ... Journal of inherited metabolic disease 42 (3), 534-544, 2019 | 137 | 2019 |
| Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia CM Santamaría, MC Chillón, R García-Sanz, C Perez, MD Caballero, ... Blood, The Journal of the American Society of Hematology 114 (1), 148-152, 2009 | 135 | 2009 |
| Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease M Biegstraaten, TM Cox, N Belmatoug, MG Berger, T Collin-Histed, ... Blood Cells, Molecules, and Diseases 68, 203-208, 2018 | 134 | 2018 |
| SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status L Lopez-Corral, ME Sarasquete, S Beà, R García-Sanz, MV Mateos, ... Leukemia 26 (12), 2521-2529, 2012 | 131 | 2012 |
| Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and-independent pathways acting on mitochondria I Marzo, P PÉREZ-GALÁN, P GIRALDO, D RUBIO-FÉLIX, A ANEL, ... Biochemical Journal 359 (3), 537-546, 2001 | 129 | 2001 |
| Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease CEM Hollak, S vom Dahl, JMFG Aerts, N Belmatoug, B Bembi, Y Cohen, ... Blood Cells, Molecules, and Diseases 44 (1), 41-47, 2010 | 122 | 2010 |
| Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics P Giraldo, M Pocoví, J Perez-Calvo, D Rubio-Félix, M Giralt Haematologica 85 (8), 792-799, 2000 | 117 | 2000 |
